Q1 Earnings Estimate for EBS Issued By HC Wainwright

Emergent BioSolutions Inc. (NYSE:EBS - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Emergent BioSolutions in a research report issued to clients and investors on Friday, March 21st. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will post earnings of $0.87 per share for the quarter. HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Emergent BioSolutions' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions' Q2 2026 earnings at $1.04 EPS, Q3 2026 earnings at $1.11 EPS and Q4 2026 earnings at $0.81 EPS.

Separately, StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Stock Down 4.7 %

Shares of EBS traded down $0.25 during mid-day trading on Monday, reaching $4.93. 1,682,666 shares of the stock traded hands, compared to its average volume of 2,606,804. Emergent BioSolutions has a 12-month low of $1.82 and a 12-month high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The firm has a market cap of $267.61 million, a price-to-earnings ratio of -1.20 and a beta of 1.80. The stock has a fifty day simple moving average of $8.24 and a 200 day simple moving average of $8.68.

Remove Ads

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.40. The company had revenue of $194.70 million for the quarter, compared to analyst estimates of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same quarter in the prior year, the company earned ($0.77) earnings per share.

Institutional Trading of Emergent BioSolutions

A number of institutional investors and hedge funds have recently modified their holdings of EBS. State Street Corp increased its stake in Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company's stock valued at $15,960,000 after buying an additional 1,713,200 shares during the last quarter. Oak Hill Advisors LP acquired a new stake in Emergent BioSolutions during the third quarter worth about $9,296,000. Millennium Management LLC raised its holdings in shares of Emergent BioSolutions by 83.0% during the 4th quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company's stock worth $14,167,000 after buying an additional 671,947 shares in the last quarter. Invesco Ltd. lifted its stake in Emergent BioSolutions by 70.9% in the 4th quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock valued at $14,722,000 after purchasing an additional 638,995 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Emergent BioSolutions by 67.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company's stock worth $10,554,000 after purchasing an additional 444,790 shares during the last quarter. 78.40% of the stock is owned by institutional investors.

Insider Transactions at Emergent BioSolutions

In other news, Director Neal Franklin Fowler sold 35,000 shares of Emergent BioSolutions stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the sale, the director now directly owns 101,100 shares of the company's stock, valued at approximately $589,413. This trade represents a 25.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is currently owned by insiders.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.